Lorukafusp alfa
Also known as: Anti-CD8/IL-2 immunocytokine, CD8-IL2, RG6279
Source Lorukafusp alfa at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lorukafusp alfa (also known as Anti‑CD8/IL‑2 immunocytokine, CD8‑IL2, RG6279) is an investigational fusion protein that couples an anti‑CD8 antibody fragment to interleukin‑2. Designed to deliver IL‑2 signaling directly to CD8⁺ T cells, it aims to boost the number and function of these cytotoxic lymphocytes. Preclinical studies suggest potential applications in cancer immunotherapy and chronic viral infections such as hepatitis B, where reactivating exhausted CD8⁺ T cells could improve disease control.
Mechanism of Action
The molecule combines a CD8‑targeting moiety with IL‑2, creating a cis‑targeted cytokine. Upon binding CD8 on the surface of cytotoxic T cells, the attached IL‑2 engages the IL‑2 receptor complex (βγ chains) on the same cell, delivering proliferative and activation signals preferentially to CD8⁺ T cells. This selective delivery avoids widespread activation of IL‑2 receptors on regulatory T cells and NK cells, thereby enhancing CD8⁺ effector functions such as interferon‑γ and granzyme B production while limiting off‑target cytokine effects.
What the Research Shows
Evidence for Lorukafusp alfa comes from preclinical and ex vivo studies. In human tumor fragments, CD8‑IL2 reactivated dysfunctional intratumoral CD8⁺ T cells, increasing effector capacity and outperforming PD‑1 blockade (Cancer Discov. 2024). In mouse models of chronic hepatitis B, the fusion protein expanded liver‑resident HBV‑specific CD8⁺ T cells, boosted interferon‑γ and granzyme B, and markedly reduced viral load and antigenemia; a parallel study in cynomolgus monkeys showed a ~20‑fold rise in peripheral CD8⁺ T cells without altering NK or Treg numbers (Sci Transl Med. 2024). No human clinical trial data are reported, and the compound remains investigational.
Reported Benefits
Preclinical data suggest Lorukafusp alfa can selectively expand and activate CD8⁺ T cells, leading to potent anti‑tumor activity in ex vivo human cancer tissue and robust antiviral effects against hepatitis B in animal models. Compared with untargeted IL‑2, the fusion protein yields greater CD8⁺ T‑cell proliferation and functional cytokine production while sparing regulatory and NK cell populations, potentially reducing the systemic toxicity seen with conventional IL‑2 therapy.
Limitations of the Evidence
All published evidence is limited to ex vivo human tissue assays, mouse hepatitis B models, and non‑human primate studies; no efficacy or safety data from human clinical trials are available. The durability of responses, optimal dosing, and effects in diverse tumor types or chronic infections remain unknown. Moreover, the long‑term impact on immune regulation and potential for cytokine‑related adverse events have not been evaluated in patients.
Safety Considerations
Preclinical reports did not describe serious adverse events, and the targeted design aims to limit the broad activation associated with high‑dose IL‑2. Nonetheless, IL‑2 can cause vascular leak, hypotension, and other cytokine‑mediated toxicities, so caution is warranted. The safety profile in humans is currently unknown, and rigorous clinical monitoring would be required in future trials.
How It Is Administered
Lorukafusp alfa is administered as an investigational biologic via intravenous or subcutaneous injection, consistent with its classification as a fusion protein. Formulations are designed for systemic delivery, but dosing regimens have not been established for clinical use.
Routes of Administration
Goals & Uses
- T cell memory expansionImmunologyLow
- Combination immunotherapyOncologyLow
- Reduction of IL-2 systemic toxicitySafety / TolerabilityModerate
- Anti-tumor immunity enhancementOncologyModerate
Contraindications
- Severe autoimmune diseaseImmunologicalHigh
- Severe organ dysfunctionOrgan FunctionModerate
- Active severe infectionInfectiousHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- Lymphopenia / lymphocyte count changesHematologicalUncommon
- Injection site reactionsLocalCommon
- Cytokine release syndrome (CRS)ImmunologicalUncommon
- Immune-related adverse events (irAEs)ImmunologicalUncommon
- FatigueGeneralCommonLow energy or tiredness
Drug Interactions
- Immunosuppressive agentsModerate
- CorticosteroidsModerate
- Anti-PD-1 / Anti-PD-L1 agentsModerate
Population Constraints
- Transplant recipients on immunosuppressionMedical HistoryRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Patients with prior severe cytokine-mediated toxicityMedical HistoryRelative
Regulatory Status
- European UnionInvestigationalClinical trials ongoing under EMA oversight; not approved.
- United StatesInvestigationalUnder IND-enabled clinical trials; no FDA approval as of early 2025.
- United KingdomInvestigationalNo MHRA approval; clinical investigation stage only.
Not approved by any regulatory authority as of early 2025. Under active clinical investigation (Phase I/II trials). Designated as investigational in the US, EU, and other jurisdictions.
Evidence & Sources
- Journal ArticleHighCoura JR, Borges-Pereira J2010-01-01T00:00:00.000000Z
- Journal ArticleLowKaptein P, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateCao ZX, Chen XP, Wu ZD2003-01-01T00:00:00.000000Z
- Journal ArticleLowAndreata F, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighZheng Y, et al.2007-01-01T00:00:00.000000Z
- Journal ArticleLowShinkai M, et al.2006-01-01T00:00:00.000000Z
Frequently Asked Questions
What makes Lorukafusp alfa different from conventional IL‑2 therapy?
Conventional IL‑2 binds receptors on many immune cells, causing widespread activation and toxicity. Lorukafusp alfa is a CD8‑targeted fusion that delivers IL‑2 directly to CD8⁺ T cells, enhancing their function while minimizing stimulation of regulatory T cells and NK cells.
Has Lorukafusp alfa been tested in patients with cancer?
To date, evidence comes from ex vivo studies using human tumor fragments, which showed reactivation of CD8⁺ T cells and superior activity to PD‑1 blockade. No clinical trial results in cancer patients have been published.
Could this drug be used to treat chronic hepatitis B infection?
In mouse models of chronic HBV, CD8‑IL2 expanded virus‑specific CD8⁺ T cells and dramatically reduced viral markers. A parallel study in monkeys confirmed CD8⁺ T‑cell expansion, but human efficacy and safety have not yet been demonstrated.
What are the known side effects of Lorukafusp alfa?
Preclinical studies reported no serious adverse events, but IL‑2–based agents can cause vascular leak, hypotension, and cytokine‑related effects. Because human safety data are lacking, potential side effects remain speculative.
Is Lorukafusp alfa currently approved for any medical use?
No. The compound is classified as investigational and has not received regulatory approval for any indication. Ongoing research is required before it can be considered for clinical use.
What is Lorukafusp alfa?
Lorukafusp alfa (also known as Anti‑CD8/IL‑2 immunocytokine, CD8‑IL2, RG6279) is an investigational fusion protein that couples an anti‑CD8 antibody fragment to interleukin‑2. Designed to deliver IL‑2 signaling directly to CD8⁺ T cells, it aims to boost the number and function of these cytotoxic lymphocytes. Preclinical studies suggest potential applications in cancer immunotherapy and chronic viral infections such as hepatitis B, where reactivating exhausted CD8⁺ T cells could improve disease control.
What is Lorukafusp alfa used for?
Lorukafusp alfa is educationally associated with: T cell memory expansion, Combination immunotherapy, Reduction of IL-2 systemic toxicity, Anti-tumor immunity enhancement. Educational only — not medical advice.
How is Lorukafusp alfa administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Lorukafusp alfa?
Reported adverse effects include: Flu-like symptoms, Lymphopenia / lymphocyte count changes, Injection site reactions, Cytokine release syndrome (CRS), Immune-related adverse events (irAEs), Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lorukafusp alfa?
Recorded contraindications: Severe autoimmune disease, Severe organ dysfunction, Active severe infection. Consult a qualified clinician before use.